Research highlights the use of multimodal
machine learning to identify non-small cell lung cancer patients
predicted to derive the most benefit from combination
immunotherapy
BOSTON and ROLLE, Switzerland, Sept. 14,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology company and a leader in
data-driven medicine, will unveil new research at the European
Society for Medical Oncology (ESMO) 2024. The study, conducted in
collaboration with AstraZeneca, leverages advanced AI-driven
techniques to identify subgroups of stage IV non-small cell lung
cancer (NSCLC) patients who could most benefit from the addition of
tremelimumab to durvalumab and chemotherapy.
The research is a retrospective, multimodal analysis of the
POSEIDON Phase 3 clinical trial (NCT03164616). This trial
originally demonstrated that the combination of tremelimumab,
durvalumab, and chemotherapy significantly increases
progression-free survival (PFS) and overall survival (OS) versus
chemotherapy in patients with metastatic NSCLC, which lead to
approval of this regiment globally in 1L mNSCLC. The SOPHiA
GENETICS study used cutting-edge multimodal machine learning models
to analyze clinical, biological, genomic, and imaging data,
pinpointing patient subgroups who are most likely to benefit from
the combination treatment.
The research highlighted signatures identifying patients with
non-squamous metastatic NSCLC who may derive higher OS benefit from
the addition of tremelimumab to durvalumab plus chemotherapy in the
first-line treatment setting. In particular, EGFR wild-type, FGFR3
wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation
comprised elements of a signature was identified as being
associated with a higher OS benefit. These findings could have
significant implications for the treatment of NSCLC, as it provides
an exploration avenue towards a more tailored approach to patient
care.
"Our collaboration with AstraZeneca represents a major step
forward in personalized oncology. Non-small cell lung cancer
remains one of the most challenging cancers to treat due to its
complex biology and the late stage at which it is often diagnosed,"
said Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA
GENETICS. "This study harnesses the power of multimodal data and
advanced AI to identify which patients are most likely to benefit
from specific therapies. By tailoring treatment strategies based on
a patient's unique multimodal profile, we aim to improve outcomes
and offer new hope to those battling this difficult disease."
The study will be presented as a poster by Ferdinandos
Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center at
ESMO 2024 hosted in Barcelona,
Spain from September 13-17,
2024. His presentation showcases the operational feasibility
and clinical impact of large-scale multimodal analyses in
identifying heterogeneous treatment effects in oncology.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to data-driven
medicine by using AI to deliver world-class care to patients with
cancer and rare disorders across the globe. It is the creator of
the SOPHiA DDM™ Platform, which analyzes complex genomic and
multimodal data and generates real-time, actionable insights for a
broad global network of hospital, laboratory, and biopharma
institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us on
LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-presents-ground-breaking-multimodal-research-on-ai-driven-patient-stratification-at-esmo-2024-302246192.html
SOURCE SOPHiA GENETICS